



DANISH HEALTH
AUTHORITY



Vaccination against SARS-CoV-2 and vaccine-induced immune thrombotic thrombocytopenia (VITT)

An international scientific webinar

Thursday, 29th April 2021, 13.00-16.20 (CET)
(07.00-10.20 EST)

Introduction

Vaccination against SARS-CoV-2 and vaccine-induced immune thrombotic thrombocytopenia (VITT)

An international scientific webinar

Thursday, 29th April 2021, 13.00-16.00 (CET) (07.00-10.00 EST)

On 11 March 2021, the Danish Health Authority suspended the use of the AstraZeneca COVID-19 vaccine (Vaxzevria®) pending national and international investigations into safety signals. "In the following four weeks, a new syndrome was described (Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT), causality was established and a Danish-Norwegian registry study that estimated the excess of VITT following Vaxzevria® as 1 per 40.000 vaccinated. Based on these findings, and a contextual assessment of the current Danish epidemic, on 14 April 2021 the Danish Health Authority decided to continue vaccine roll-out in Denmark without Vaxzevria® within the national COVID-19 vaccine program.

The aim of this webinar is to share insights and considerations in a transparent manner. Thus, the webinar will present the latest information on the epidemiology, possible pathophysiology, diagnosis, treatment and public health implications of VITT.

Each session consists of comprehensive presentations followed by discussion, which is moderated by experts.

Programme: During the 3-hour virtual webinar, comprehensive presentations will be followed by discussions, which will be moderated by the respective experts.

Registration is required, but the webinar is open to all, free of charge.

Please register here: <https://sst.evenzu.com>

Programme

13.00-13.05 Welcome

Søren Brostrøm, MD, PhD, MPA, Director General,
Danish Health Authority, Denmark

13.05-14.00 Session 1:

Discovery of the adverse events Introduction to the theme and purpose of the webinar

Chair: Anne Mette Hvas, Professor, MD, PhD, Deputy Head of Department,
Aarhus University, Denmark

The Danish experience: reactions by the authorities, scientific investigations, and public health reflections

Søren Brostrøm, MD, PhD, MPA, Director General,
Danish Health Authority, Denmark

Pharmaco-epidemiological investigations within the Norwegian and Danish cohort

Anton Pottegård, Professor, MSc, PhD, University of Southern Denmark

The German experience

Andreas Greinacher, Professor, MD, DMSc. University of Greifswald, Germany

Panel discussion:

Session speakers including Beverly J. Hunt, Professor, MD, King's College
London, UK.

14.00-14.05 Break

14.05-14.50 Session 2:

Clinical care perspectives on vaccine-induced immune thrombotic thrombocytopenia (VITT)

Chair: Lars Østergaard, Clinical Professor, MD, PhD, Chief Physician, Chair,
Aarhus University, Denmark

Proposed case-definition of VITT and treatment algorithm

Jakob Stensballe, Senior Consultant, MD, PhD, Rigshospitalet, Denmark

Biomarker investigations and genetic studies

Sisse Rye Ostrowski, Professor, Consultant, PhD, DMSc, Rigshospitalet and
University of Copenhagen, Denmark

Panel discussion: State-of-the-art diagnosis & treatment of VITT

Anne Mette Hvas, Professor, MD, PhD, Deputy Head of Department, Aarhus University, Denmark

Jakob Stensballe, Senior Consultant, MD, PhD, Rigshospitalet, Denmark

Sisse Rye Ostrowski, Professor, Consultant, PhD, DMSc, Rigshospitalet and University of Copenhagen, Denmark

Andreas Greinacher, Professor, MD, DMSc., University of Greifswald, Germany

Beverly J. Hunt, Professor, MD, King's College London, UK.

14.50-14.55 Break

14.55-15.25 **Session 3:**

The importance of different adenovirus vectors in VITT

Chair: Jens Lundgren, Professor, MD, DMSc, Senior Consultant, Academic Chair, Director, Rigshospitalet and University of Copenhagen, Denmark

US-experience from the rollout of the J&J vaccine

Speaker to be announced

Discussion

Jens Lundgren, Professor, MD, DMSc, Rigshospitalet and University of Copenhagen, Denmark

and speaker

15.25-15.30 Break

15.30-16.15 **Session 4:**

Difficult dilemma: the public health benefits versus risks

Chair: Jesper Hallas, Professor, MD, Dr.Med.Sc, University of Southern Denmark

What can health economics contribute with?

Trygve Ottersen, MD, PhD, Executive Director, Management and Staff for Health Services, Norwegian Institute of Public Health, Norway

Panel discussion

Representative from WHO Europe (tbc)

Representative from European Medicines Agency (tbc)

Camilla Stoltenberg, MD, PhD, Director General,
Norwegian Institute of Public Health, Norway

Søren Brostrøm, MD, PhD, MPA, Director General,
Danish Health Authority, Denmark

16.15-16.20 Closing remarks

Søren Brostrøm, MD, PhD, MPA, Director General,
Danish Health Authority, Denmark

